ÂÜÀòÂÒÂ×

Phil Herman has served as their EVP, Commercial and New Product Development since January of 2022. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases and has a proven track record of product launches across a broad spectrum of therapeutic areas.

Mr. Herman most recently served as the Chief Commercial Officer of Y-mAbs Therapeutics where he led the successful launch and commercialization of DANYELZA® (naxitamab). He served in this role from June 2018 to December 2021. Prior to Y-mAbs, Mr. Herman held various commercial and marketing positions including VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax, Director of Marketing at Vanda Pharmaceuticals, and various positions of increasing responsibility at Pfizer Inc.

Mr. Herman holds a B.A. in Business Administration from Baldwin Wallace University, and an M.B.A. from the Kellogg School of Management at Northwestern University.